Cognition Therapeutics, Inc. CGTX
0.62 USD -0.01 (-2.35%)
As ofNov 18, 2026, 12:26 PM EST
0.6012 Day range 0.6399
0.55 52-week range 1.81
- YTD
- -54.44%
- 1 year
- -59.53%
News
globenewswire.com Cognition Therapeutics Announces CTAD Poster Highlighting Screening Efficiencies with p-Tau217 in the Ongoing Phase 2 START Study - Efficient screening processes may reduce participant and site burden in clinical trials - PURCHASE, N.Y., Nov. 17, 2026 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition)…benzinga.com Cognition Therapeutics Q3 EPS $(0.04) Beats $(0.07) Estimate Cognition Therapeutics (NASDAQ:CGTX) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.07) by 42.86 percent. This is a 33.33 percent increase over losses…
benzinga.com Cognition Therapeutics Aligns With FDA On Key Elements Of Phase 3 Study In Dementia With Lewy Bodies Including Patient Selection, Dose, Duration, And Endpoints The planned registrational study is expected to enroll participants with mild-to-moderate DLB who will be randomized to receive either 100 mg of once-daily oral zervimesine or placebo for nine…
